Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CRVS stock hub

Corvus Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CRVSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.3B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CRVS

In the news

Latest news · CRVS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-30.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-20.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CRVS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001626971
Company name	Corvus Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	221015100
Employees	37
Employees Change	6%
Employees Change Percent	19.35
Enterprise value	$1.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2016-03-23
Isin	US2210151005
Last refreshed	2026-05-10
Market cap	$1.3B
Market cap category	Small-Cap
Price	$15.55
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	CRVS
Website	https://www.corvuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.38%
FCF yield	-2.69%
P/B ratio	5.43x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-44.2M
Net Income Growth Years	1%
Profit Per Employee	$-1.2M
ROA	-19.16
Roa5y	-28.24
ROCE	-19.88
ROE	-30.46
Roe5y	-73.89
ROIC	-20.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	2.55%
Cagr1y	386.46%
Cagr3y	134.84%
Cagr5y	39.83%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$253.2M
Cash	$236.7M
Current Assets	$239.9M
Current Liabilities	$12.1M
Debt	$834,000
Debt Equity	$0
Equity	$240.7M
Liabilities	$12.5M
Long Term Assets	$13.2M
Long Term Liabilities	$406,000
Net Cash	$235.9M
Net Cash By Market Cap	$18.04
Net Cash Growth	447.81%
Net Debt Equity	$-0.98
Tangible Book Value	$240.7M
Tangible Book Value Per Share	$2.86
WACC	9.39

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	19.81
Net Working Capital	$-8.5M
Quick ratio	19.55
Working Capital	$227.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-24.98%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	28.62%
1Y total return	385.94%
200-day SMA	10.78
3Y total return	1,195.83%
50-day SMA	15.44
50-day SMA vs 200-day SMA	50over200
5Y total return	434.36%
All Time High	26.95
All Time High Change	-42.3%
All Time High Date	2026-01-23
All Time Low	0.61
All Time Low Change	2,461.78%
All Time Low Date	2023-03-28
ATR	1.14
Beta	0.94
Beta1y	-0.33
Beta2y	0.93
Ch YTD	101.9
High	15.8
High52	26.95
High52 Date	2026-01-23
High52ch	-42.3%
Low	14.75
Low52	3.17
Low52 Date	2025-05-08
Low52ch	390.69%
Ma50ch	0.73%
Premarket Change Percent	3.22
Premarket Price	$15.06
Premarket Volume	3,853
Price vs 200-day SMA	44.22%
RSI	50.3
RSI Monthly	65.5
RSI Weekly	55.95
Sharpe ratio	1.38x
Sortino ratio	5.65
Total Return	-24.98%
Tr YTD	101.9
Tr1m	8.36%
Tr1w	0.58%
Tr3m	-24%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$27
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.15
Earnings Revenue Estimate	620,000x
Operating Income	$-47.9M
Price target	$30.17
Price Target Change	$94.02
Price Target Change Top	$73.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	71,342,846%
Float Percent	84.84%
Shares Insiders	3.51%
Shares Institutions	49.42%
Shares Out	84,090,424
Shares Qo Q	8.48%
Shares Yo Y	24.98%
Short Float	23.73%
Short Ratio	14.04
Short Shares	20.13

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-41.9M
Average Volume	1,330,821.35x
Bv Per Share	2.86
CAPEX	$-229,000
Ch10y	28.62
Ch1m	8.36
Ch1w	0.58
Ch1y	385.9
Ch3m	-24
Ch3y	1,195.8
Ch5y	434.4
Ch6m	104.6
Change	6.58%
Change From Open	5
Close	14.59
Days Gap	1.51
Depreciation Amortization	112,000
Dollar Volume	15,247,194.9
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-47.9M
EBITDA	$-47.8M
EPS	$-0.85
F Score	2
FCF	$-35.1M
FCF EV Yield	-3.28x
FCF Per Share	$-0.42
Financing CF	226,896,000
Fiscal Year End	December
Founded	2,014
Investing CF	-156,885,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-12
Ma150	12.54
Ma150ch	23.96%
Ma20	15.69
Ma20ch	-0.91%
Net CF	35,103,000
Next Earnings Date	2026-08-06
Open	14.81
Optionable	Yes
Position In Range	76.19
Post Close	15.55
Postmarket Change Percent	1.29
Postmarket Price	$15.75
Ppne	1,033,000
Pre Close	14.59
Price Date	2026-05-08
Ptbv Ratio	5.43
Relative Volume	0.74x
Share Based Comp	6,729,000
Tr6m	104.61%
Us State	California
Volume	980,527

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CRVS pay a dividend?

Capital-return profile for this ticker.

Performance

CRVS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CRVS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+49.4%

Float: +84.8% of shares outstanding

Insider ownership

+3.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CRVS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.3

Neutral momentum band

Price vs 200-day MA

+44.2%

50/200-day relationship not available

Beta (5Y)

0.94

Moves roughly with the market

Sharpe ratio

1.38

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CRVS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CRVS stock rating?

Corvus Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CRVS analysis?

The full report lives at /stocks/CRVS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CRVS?

The latest report frames CRVS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CRVS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.